Package Leaflet: Information for the Patient
Brivaracetam Viso Farmacéutica 10 mg film-coated tablets EFG
Brivaracetam Viso Farmacéutica 25 mg film-coated tablets EFG
Brivaracetam Viso Farmacéutica 50 mg film-coated tablets EFG
Brivaracetam Viso Farmacéutica 75 mg film-coated tablets EFG
Brivaracetam Viso Farmacéutica 100 mg film-coated tablets EFG
Read the entire package leaflet carefully before you start taking this medicine, because it contains important information for you.
What is Brivaracetam Viso Farmacéutica
Brivaracetam Viso Farmacéutica contains the active substance brivaracetam. It belongs to a group of medicines called “antiepileptics”. These medicines are used to treat epilepsy.
What Brivaracetam Viso Farmacéutica is used for
Severe skin reactions, including Stevens-Johnson syndrome, have been reported with brivaracetam treatment. Do not take brivaracetam and contact your doctor immediately if you notice any of the symptoms related to these severe skin reactions described in section 4.
Consult your doctor or pharmacist before starting to take brivaracetam:
Brivaracetam is not recommended for use in children under 2 years of age.
Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.
In particular, tell your doctor if you are taking any of the following medicines, because your doctor may need to adjust your dose of brivaracetam:
Women of childbearing age should discuss the use of contraceptives with their doctor.
If you are pregnant or breastfeeding, think you may be pregnant or are planning to have a baby, consult your doctor or pharmacist before taking this medicine.
It is not recommended to take brivaracetam if you are pregnant, as the effects of brivaracetam on pregnancy and the fetus are unknown.
It is not recommended to breastfeed your baby while taking brivaracetam, as brivaracetam is excreted in breast milk.
Do not stop treatment without consulting your doctor first. Stopping treatment may increase the number of seizures you have and harm your baby.
This medicine contains less than 1 mmol of sodium (23 mg) per tablet; this is, essentially “sodium-free”.
Follow the instructions for administration of this medicine exactly as prescribed by your doctor. If you are unsure, consult your doctor or pharmacist again. Other forms of this medicine may be more suitable for some patients, e.g. children (if they cannot swallow whole tablets, for example). Consult your doctor or pharmacist.
You will take brivaracetam together with other medicines to treat epilepsy.
Dose
Your doctor will calculate the correct daily dose for you. Take the daily dose divided into two equal doses, approximately 12 hours apart.
Adolescents and children weighing 50 kg or more, and adults
Adolescents and children weighing between 20 kg and less than 50 kg
Children weighing between 10 kg and less than 20 kg
Patient with liver problems
If you have liver problems:
Brivaracetam is a long-term treatment – continue taking this medicine until your doctor tells you to stop.
If you take more brivaracetam than you should, consult your doctor. You may feel dizzy and drowsy. You may also experience some of the following symptoms: feeling unwell, feeling like you are spinning, problems with balance, anxiety, feeling very tired, irritability, aggression, difficulty sleeping, depression, thoughts or attempts to harm yourself or commit suicide.
If you have any further questions on the use of this medicine, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
Very common:may affect more than 1 in 10 people.
Common:may affect up to 1 in 10 people.
Uncommon:may affect up to 1 in 100 people
Frequency not known:cannot be estimated from the available data
Common:may affect up to 1 in 10 people.
If you experience any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this package leaflet. You can also report side effects directly via the Spanish Medicines Vigilance System for Human Use: www.notificaRAM.es. By reporting side effects, you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the carton and blister after EXP. The expiry date refers to the last day of the month shown.
This medicine does not require any special storage conditions.
Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help protect the environment.
Core: microcrystalline cellulose, pregelatinized starch (from maize), sodium croscarmellose, magnesium stearate (see section 2, “Brivaracetam Viso Farmacéutica contains sodium”).
Tablet coating:
Brivaracetam Viso Farmacéutica 10 mg are white or almost white, round, biconvex film-coated tablets, 6 mm in diameter, engraved with “10” on one side.
Brivaracetam Viso Farmacéutica 25 mg are grey, oval, biconvex film-coated tablets, 9 x 5 mm, engraved with “25” on one side.
Brivaracetam Viso Farmacéutica 50 mg are yellow, oval, biconvex film-coated tablets, 12 x 7 mm, engraved with “50” on one side.
Brivaracetam Viso Farmacéutica 75 mg are pink, oval, biconvex film-coated tablets, 13 x 7 mm, engraved with “75” on one side.
Brivaracetam Viso Farmacéutica 100 mg are grey-green, oval, biconvex film-coated tablets, 15 x 8 mm, engraved with “100” on one side.
Brivaracetam Viso Farmacéutica tablets are packaged in blisters included in cardboard boxes containing 14 or 56 film-coated tablets, or 100 x 1 film-coated tablets in unit dose blisters.
The 10 mg, 25 mg, 50 mg and 75 mg film-coated tablets may also be packaged in multiple packs containing 168 (2 packs of 84) film-coated tablets.
The 100 mg film-coated tablets may also be packaged in multiple packs containing 168 (3 packs of 56) film-coated tablets.
All packs are available in Aluminium/Aluminium (OPA/Aluminium/PVC) blisters.
Not all pack sizes may be marketed.
Marketing authorisation holder
Glenmark Arzneimittel GmbH
Industriestr. 31
82194 Gröbenzell
Germany
Holsten Pharma GmbH
Hahnstraße 31-35
60528 Frankfurt am Main
Germany
You can request more information about this medicine from the local representative of the marketing authorisation holder:
Viso Farmacéutica S.L.U.
C/ Retama 7, 7th floor
28045 Madrid
Spain
This medicine is authorised in the Member States of the European Economic Area under the following names:
Germany Brivaracetam Glenmark 10 mg film-coated tablets
Brivaracetam Glenmark 25 mg film-coated tablets
Brivaracetam Glenmark 50 mg film-coated tablets
Brivaracetam Glenmark 75 mg film-coated tablets
Brivaracetam Glenmark 100 mg film-coated tablets
Denmark Brivaracetam Glenmark
Spain Brivaracetam Viso Farmacéutica 10 mg film-coated tablets EFG
Brivaracetam Viso Farmacéutica 25 mg film-coated tablets EFG
Brivaracetam Viso Farmacéutica 50 mg film-coated tablets EFG
Brivaracetam Viso Farmacéutica 75 mg film-coated tablets EFG
Brivaracetam Viso Farmacéutica 100 mg film-coated tablets EFG
Finland Brivaracetam Glenmark 10 mg film-coated tablets
Brivaracetam Glenmark 25 mg film-coated tablets
Brivaracetam Glenmark 50 mg film-coated tablets
Brivaracetam Glenmark 75 mg film-coated tablets
Brivaracetam Glenmark 100 mg film-coated tablets
Italy Brivaracetam Glenmark 10 mg film-coated tablets
Brivaracetam Glenmark 25 mg film-coated tablets
Brivaracetam Glenmark 50 mg film-coated tablets
Brivaracetam Glenmark 75 mg film-coated tablets
Brivaracetam Glenmark 100 mg film-coated tablets
Netherlands Brivaracetam Glenmark 10 mg film-coated tablets
Brivaracetam Glenmark 25 mg film-coated tablets
Brivaracetam Glenmark 50 mg film-coated tablets
Brivaracetam Glenmark 75 mg film-coated tablets
Brivaracetam Glenmark 100 mg film-coated tablets
Norway Brivaracetam Glenmark
Sweden Brivaracetam Glenmark
Slovakia Brivaracetam Glenmark 10 mg
Brivaracetam Glenmark 25 mg
Brivaracetam Glenmark 50 mg
Brivaracetam Glenmark 75 mg
Brivaracetam Glenmark 100 mg
Detailed information on this medicine is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) (http://www.aemps.gob.es/).